| Market Cap | 96.90K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.63M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -79.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | - | Quick Ratio | 0.06 | Shares Outstanding | 8.81M | 52W Low Chg | 10,900.00% |
| Insider Own | - | ROA | -594.37% | Shares Float | - | Beta | -9.60 |
| Inst Own | 1.55% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00110 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,993 | Target Price | 10.30 |
| Oper. Margin | - | Earnings Date | - | Volume | 150,630 | Change | 0.00% |
AtheroNova Inc., a development stage company, is engaged in the research, development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. The company develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. Its lead compound includes AHRO-001, an active pharmaceutical ingredient. The company also focuses on developing various applications for its patented and patents-pending therapies in market sectors that comprise cardiovascular disease, stroke, and peripheral artery disease. AtheroNova Inc. was founded in 2006 and is based in Irvine, California.